Brind.

Jazz Pharmaceuticals has a recently licensed medication called Modeyso, which was licensed as of September 2, 2025.

5 reports, 4 independent Updated Sep 2
Gone quiet Reached 4 outlets in its first 24 hours
Reports
5
Developments
2
Repetition
60%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Jazz Pharmaceuticals has a recently licensed medication called Modeyso, which was licensed as of September 2, 2025.

Who's involved

What this event is mainly about
Jazz Pharmaceuticals

How it developed

Newest first. Tap a step to see who reported it.
  1. Jazz Pharmaceuticals' Modeyso is a recently licensed medication.1 source
  2. FDA granted approval for Modeyso, a drug developed by Jazz Pharmaceuticals.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyJazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the best mid-cap stocks with huge upside potential. Truist
  • Insider MonkeyJazz Pharmaceuticals plc (JAZZ) Wins FDA Accelerated Approval for Modeyso™ Brain Cancer Therapy We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Jazz Pharmaceuticals p
  • PR NewswireJazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on
  • GlobeNewswireOnco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nati
  • StockStoryWhy Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 4.8% in the afternoon session after the company received accelerated ap